Mindfulness-Based Substance Use Prevention (MINDS-UP) (MINDS-UP)

September 22, 2026 updated by: David Saunders, MD PhD, New York State Psychiatric Institute

Mindfulness-Based Substance Use Prevention (MINDS-UP): a Randomized Controlled Trial

The goal of this clinical trial is to test the feasibility, behavioral/neural mechanisms, and preliminary efficacy of "MINDfulness-based Substance Use Prevention Program," or "MINDS-UP", a novel substance use prevention meditation intervention for children and adolescents between the ages of 10 and 14. The aims of the study are:

Aim 1: Determine feasibility and acceptability of MINDS-UP as a preventive intervention via a) retention, b) attendance, c) teacher-rated participation, d) student-rated participation, e) homework completion, and f) acceptability.

Aim 2: Evaluate neuropsychological mechanisms (target engagement) of MINDS-UP.

Aim 3 (Exploratory): Assess preliminary efficacy of MINDS-UP on substance use initiation (SUI).

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

10 years to 14 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Youth is ages 10-14 years on the day of screening [i.e., does not turn 15 before or on the day of screening]
  2. Youth has access to a smartphone, tablet, or computer with Wi-Fi
  3. Youth and parent are English-speaking

Exclusion Criteria:

1. The youth has been diagnosed with or received treatment for one of the following mental health problems: depression, bipolar disorder, schizophrenia, autism spectrum disorder, intellectual disability, or substance use disorder.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Sport: Prevention Plus Wellness (PPW)

Sport: Prevention Plus Wellness (PPW) is a brief, evidence-based substance use prevention program for youth. PPW consists of a single self-administered 45-minute session that is interactive and intended for use by youth in the home setting. It involves screening youth to increase awareness of their current health behaviors; motivational enhancement for change; and establishing a behavior goal plan.

PPW is a standardized, empirically-based intervention for substance use prevention in adolescents ages 10-14. It consists of 1 45 minute self-administered online course.

Other Names:
  • PPW
Experimental: PPW + MINDS-UP

MINDS-UP consists of 4 x 60-minute sessions, once weekly over 4 weeks. MINDS-UP will be delivered to participants remotely, in a 1:1 setting, taught by the meditation teachers that will be hired and trained by Dr. Saunders. Additionally, participants will be provided audio files of 5-10-minute guided meditation practices, led by Dr. Saunders, as homework. Participants randomized to MINDS-UP will also complete PPW, a 45 minute, self-administered course.

PPW is a standardized, empirically-based intervention for substance use prevention in adolescents ages 10-14. It consists of 1 45 minute self-administered online course.

Other Names:
  • PPW

MINDS-UP is a substance use prevention program for children/adolescents.It consists of 4 x 60-minute sessions, once weekly over 4 weeks. The four MINDS-UP classes will focus on the following: Mindfulness of Body; Mindfulness of Mind; Mindfulness of Environment/Community; Kindness, Compassion, Joy and Equanimity, respectively.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Retention
Time Frame: Completion of Study (up to 36 months)

Percent of participants who completed all study procedures among those who were randomized

Completion of Study (up to 36 months)
Attendance
Time Frame: Completion of Study (up to 36 months)

Percent of scheduled sessions that were completed by the participant.

Completion of Study (up to 36 months)
Teacher Rated Participation
Time Frame: Completion of Study (up to 36 months)

Research Assessment Package for Schools - Teacher Rated

Completion of Study (up to 36 months)
Student-Rated Participation
Time Frame: Completion of Study (up to 36 months)

Research Assessment Package for Schools - Student Engagement

Completion of Study (up to 36 months)
Homework Completion
Time Frame: Completion of Study (up to 36 months)

Percentage of assigned homeworks that were completed by the participant.

Completion of Study (up to 36 months)
Acceptability
Time Frame: Completion of Study (up to 36 months)

Acceptability of Intervention Measure

Completion of Study (up to 36 months)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total Problems (parent-report)
Time Frame: 4-8 weeks, 6 months, and 12 months

Pre-assessment to post-assessment (and 6- and 12-month follow-up) difference in the total score on the total problems subscale on the Child Behavior Checklist (CBCL), which is comprised of 98 questions; individual item scores range from 0 to 2; higher scores indicate higher amount of behavioral problems

4-8 weeks, 6 months, and 12 months
ADHD Symptoms
Time Frame: 4-6 weeks, 6 months, and 12 months

Pre-assessment to post-assessment (and 6- and 12-month follow-up) difference in score on the ADHD Rating Scale, an 18-item parent-report assessment that measures adolescent behaviors related to ADHD (inattentiveness, hyperactivity).

4-6 weeks, 6 months, and 12 months
Suicidal Thoughts/Behaviors
Time Frame: 4-6 weeks, 6 months, 12 months

The C-SSRS is a gold-standard assessment tool for suicide risk. This tool will be administered at every visit.

4-6 weeks, 6 months, 12 months
Alcohol sipping
Time Frame: 4-6 weeks, 6 months, and 12 months

Low-level and early alcohol use as characterized by the iSay Sipping Inventory. This survey characterizes low level and first/early alcohol use, including age at first sip, whether that drink was completed, and behaviors after the first sip.

4-6 weeks, 6 months, and 12 months
Tobacco Use
Time Frame: 4-6 weeks, 6 months, and 12 months

Tobacco use as measured by Tobacco Low Level Use Measure. This is a short tool that measures number of times used, type of tobacco/nicotine used, duration of use, and frequency of use.

4-6 weeks, 6 months, and 12 months
Cannabis Use
Time Frame: 4-6 weeks, 6 months, and 12 months

Cannabis use as measured by the Marijuana Low-Level Use Measure, a short tool that measures early/first use of cannabis.

4-6 weeks, 6 months, and 12 months
Total Problems (adolescent report)
Time Frame: 4-6 weeks, 6 months, 12 months

The Youth Self Report (YSR) is the self-report adolescent version of the Child Behavior Checklist, and is used to assess emotional and behavioral problems in children and adolescents.

4-6 weeks, 6 months, 12 months
Mindfulness
Time Frame: 4-6 weeks, 6 months, and 12 months

Pre-assessment to post-assessment (and 6- and 12-month follow-up) difference in score on the Child and Adolescent Mindfulness Measure (CAMM); the CAMM is a 10-item measure of self-reported mindfulness; scores range from 0 to 40, with higher scores indicating higher mindfulness

4-6 weeks, 6 months, and 12 months
Anxiety and Depression
Time Frame: 4-6 weeks, 6 months, and 12 months

Pre-assessment to post-assessment (and 6 and 12 month-follow-up) difference in score on the Revised Childhood Anxiety and Depression scale, a 47-item self-report scale that assesses childhood/adolescent anxiety and depression symptoms across six sub-domains.

4-6 weeks, 6 months, and 12 months
Perceived Tolerance of Use
Time Frame: baseline

The Perceived Tolerance of Use is a tool that assesses peer tolerance of use of substance use (of substances that a participant has heard of, meaning the number of items is variable). It is a tool that is used in the ABCD study and the Monitoring the Future Study, the two most comprehensive studies of adolescent substance use.

baseline
Perceived Harm of Substance Use
Time Frame: baseline

The Perceived Harm of Substance Use tool assesses perceived harm of substance use (of substances that a participant has heard of, meaning the number of items is variable). It is used in the ABCD study and the Monitoring the Future Study, the two most comprehensive studies of adolescent substance use.

baseline
Beliefs About Alcohol Effects
Time Frame: baseline

The Brief Comprehensive Effects of Alcohol Questionnaire is a 15-item self-report version of the Comprehensive Effects of Alcohol Questionnaire that is used by the ABCD study to assess an adolescent's expectations of using alcohol.

baseline
Beliefs About Smoking Effects
Time Frame: baseline

The Adolescent Smoking Consequences Questionnaire (ASCQ) is a 30-item self-report instrument used to assess outcome expectancies of cigarette smoking among adolescents.

baseline
Beliefs About Cannabis Effects
Time Frame: baseline

Brief -Marijuana Effect Expectancies Questionnaire (MEEQ-B) is a 6-item self-report assessment of an adolescent's expected effect of marijuana.

baseline
Risk and Protective Factors
Time Frame: Baseline

The Community Risk and Protective Factors Survey is a 24-item parent-report tool to assess adolescent's experience of exposure to substance use risk and protective factors in the community.

Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 1, 2026

Primary Completion (Estimated)

January 1, 2028

Study Completion (Estimated)

January 1, 2028

Study Registration Dates

First Submitted

August 15, 2024

First Submitted That Met QC Criteria

September 9, 2024

First Posted (Actual)

September 19, 2024

Study Record Updates

Last Update Posted (Actual)

September 25, 2026

Last Update Submitted That Met QC Criteria

September 22, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • #Pro00076319
  • K12DA000357 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.